As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

CLICK HERE FOR CME CREDIT

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic